Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials

References

• Joerger M. Treatment regimens of classical and newer taxanes. Cancer Chemother Pharmacol. 2016;77(2):221–233. doi:10.1007/s00280-015-2893-626589792
   PubMed Web of Science ®Google Scholar
• Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumors: a systematic review of clinical data. Lancet Oncol. 2005;6(4):229–239. doi:10.1016/S1470-2045(05)70094-215811618
   PubMed Web of Science ®Google Scholar
• Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998;16(1):187–196. doi:10.1200/JCO.1998.16.1.1879440742
   PubMed Web of Science ®Google Scholar
• Engels FK, Sparreboom A, Mathot RAA, Verweij J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer. 2005;93(2):173–177. doi:10.1038/sj.bjc.660269816012521
   PubMed Web of Science ®Google Scholar
• Gerritsen-van Schieveen P, Royer B. Therapeutic drug monitoring group of the French Society of Pharmacology and Therapeutics. Level of evidence for therapeutic drug monitoring of taxanes. Fundam Clin Pharmacol. 2011;25(4):414–424. doi:10.1111/j.1472-8206.2010.00874.x20840221
   PubMed Web of Science ®Google Scholar
• Bruno R, Vivier N, Veyrat-Follet C. Montay G Rhodes GR. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs. 2001;19(2):163–169. doi:10.1023/A:101068701771711392450
   PubMed Web of Science ®Google Scholar
• Ozawa K, Minami H, Sato H. Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. Cancer Chemother Pharmacol. 2008;62(3):551–557. doi:10.1007/s00280-007-0648-818064462
   PubMed Web of Science ®Google Scholar
• Charles KA, Rivory LP, Stockler MR, et al. Predicting the toxicity of weekly docetaxel in advanced cancer. Clin Pharmacokinet. 2006;45(6):611–622. doi:10.2165/00003088-200645060-0000416719542
   PubMed Web of Science ®Google Scholar
• Baker SD, Li J, Ten Tije A, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther. 2005;77(1):43–53. doi:10.1016/j.clpt.2004.09.00515637530
   PubMed Web of Science ®Google Scholar
• Minami H, Kawada K, Sasaki Y, et al. Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Cancer Sci. 2006;97(3):235–241. doi:10.1111/j.1349-7006.2006.00166.x16542221
   PubMed Web of Science ®Google Scholar
• Patel M, Palini S, Chakravarty A, Yang J, Shyu WC, Mettetal JT. Dose schedule optimization and the pharmacokinetic driver of neutropenia. PLoS One. 2014;9(10):e109892. doi:10.1371/journal.pone.010989225360756
   PubMed Web of Science ®Google Scholar
• Gervais R, Ducolone A, Breton JL, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2005;16(1):90–96. doi:10.1093/annonc/mdi01815598944
   PubMed Web of Science ®Google Scholar
• Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004;15(9):1358–1365. doi:10.1093/annonc/mdh34915319242
   PubMed Web of Science ®Google Scholar
• Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008;112(7):1455–1461. doi:10.1002/cncr.2332118300256
   PubMed Web of Science ®Google Scholar
• Schröder CP, de Munck L, Westermann AM, et al. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel. Eur J Cancer. 2011;47(9):1355–1362. doi:10.1016/j.ejca.2010.12.01821251813
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Harbeck N, Gröll de Rivera I, et al. Prospective multicenter randomized Phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer. Oncology. 2010;79(3–4):197–203. doi:10.1159/00032064021358207
   PubMed Web of Science ®Google Scholar
• Engels FK, Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer. 2005;41(8):1117–1126. doi:10.1016/j.ejca.2005.02.01615911234
   PubMed Web of Science ®Google Scholar
• Lilenbaum R, Rubin M, Samuel J, et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol. 2007;2(4):306–311. doi:10.1097/01.JTO.0000263713.38826.8e17409802
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Licitra S, Moretti E, Pestrin M, Zafarana E, Di Leo A. Taxanes in the elderly: can we gain as much and be less toxic? Crit Rev Oncol Hematol. 2009;70(3):262–271. doi:10.1016/j.critrevonc.2008.07.01718762431
   PubMed Web of Science ®Google Scholar
• Baker SD, Zhao M, Lee CKK, et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res. 2004;10(6):1976–1983. doi:10.1158/1078-0432.CCR-0842-0315041715
   PubMed Web of Science ®Google Scholar
• Banna GL, Collovà E, Gebbia V, et al. Anticancer oral therapy: emerging related issues. Cancer Treat Rev. 2010;36(8):595–605. doi:10.1016/j.ctrv.2010.04.00520570443
   PubMed Web of Science ®Google Scholar
• Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist. 2001;6(4):12–16. doi:10.1634/theoncologist.6-suppl_4-12
   Google Scholar
• Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer. 2008;62(1):85–91. doi:10.1016/j.lungcan.2008.02.00918372075
   PubMed Web of Science ®Google Scholar
• Lay Le K, Myon E, Hill S, et al. Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ. 2007;8(2):145–151. doi:10.1007/s10198-006-0034-117333088
   PubMed Web of Science ®Google Scholar
• Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17(2):239–245. doi:10.1093/annonc/mdj02316344278
   PubMed Web of Science ®Google Scholar
• Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15(1):100–115. doi:10.1200/JCO.1997.15.1.110
   Web of Science ®Google Scholar
• Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med. 1992;35(12):1505–1509. doi:10.1016/0277-9536(92)90053-S1283035
   PubMed Web of Science ®Google Scholar
• Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42(7):665–685. doi:10.2165/00003088-200342070-0000512844327
   PubMed Web of Science ®Google Scholar
• Sawicki E, Beijnen JH, Schellens JHM, Nuijen B. Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. Int J Pharm. 2016;511(2):765–773. doi:10.1016/j.ijpharm.2016.07.06827480397
   PubMed Web of Science ®Google Scholar
• Moes JJ, Koolen SLW, Huitema ADR, Schellens JHM, Beijnen JH, Nuijen B. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Int J Pharm. 2011;420(2):244–250. doi:10.1016/j.ijpharm.2011.08.04121907780
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 2002;62(21):6158–6164.12414642
   PubMed Web of Science ®Google Scholar
• Oostendorp RL, Huitema A, Rosing H, et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2009;15(12):4228–4233. doi:10.1158/1078-0432.CCR-08-294419509162
   PubMed Web of Science ®Google Scholar
• Von Hentig N, Haberl A. Safety of pharmacoenhancers for HIV therapy. Expert Rev Clin Pharmacol. 2012;5(5):557–568. doi:10.1586/ecp.12.4523121278
   PubMed Web of Science ®Google Scholar
• De Weger VA, Stuurman FE, Koolen SLW, et al. A phase I dose escalation study of once weekly oral administration of docetaxel as ModraDoc001 capsule or ModraDoc006 tablet in combination with ritonavir. Clin Cancer Res. 2019;25(18):5466–5474. doi:10.1158/1078-0432.CCR-17-229931217201
   PubMed Web of Science ®Google Scholar
• De Weger VA, Stuurman FE, Hendrikx JJMA, et al. A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. Eur J Cancer. 2017;86:217–225. doi:10.1016/j.ejca.2017.09.01029031170
   PubMed Web of Science ®Google Scholar
• Hendrikx JJMA, Hillebrand MJ, Thijssen B, et al. A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(28):2984–2990. doi:10.1016/j.jchromb.2011.08.034
   PubMed Web of Science ®Google Scholar
• R Core Development Team. R: A language and environment for statistical computing. 2009.
   Google Scholar
• Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18(12):2354–2362. doi:10.1200/JCO.2000.18.12.235410856094
   PubMed Web of Science ®Google Scholar
• Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol. 2006;24(31):4963–4970. doi:10.1200/JCO.2005.05.029417033039
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1.). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Hendrikx JJMA, Stuurman FE, Song JY, et al. No relation between docetaxel administration route and high-grade diarrhea incidence. Pharmacol Res Perspect. 2020;00:e00633.
   Google Scholar
• De Vries Schultink AHM, Crombag MBS, Van Werkhoven E, et al. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: a meta-analysis and evaluation of a clinical cohort. Cancer Med. 2019;8(4):1406–1415. doi:10.1002/cam4.200330802002
   PubMed Web of Science ®Google Scholar
• Engels FK, Loos WJ, Van der Bol JM, et al. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Canc Res. 2011;17(2):353–362. doi:10.1158/1078-0432.CCR-10-1636
   PubMed Web of Science ®Google Scholar
• Yu H, Janssen JM, Sawicki E, et al. A population pharmacokinetic model of oral docetaxel coadministered with ritonavir to support early clinical development. J Clin Pharmacol. 2020;60(3):340–350. doi:10.1002/jcph.153231595980
   PubMed Web of Science ®Google Scholar
• Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 1993;53(5):1037.8094996
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. Br J Clin Pharmacol. 2015;80(3):342–350. doi:10.1111/bcp.1266825923589
   PubMed Web of Science ®Google Scholar
• Eichbaum C, Cortese M, Blank A, Burhenne J, Mikus G. Concentration effect relationship of CYP3A inhibition by ritonavir in humans. Eur J Clin Pharmacol. 2013;69(10):1795–1800. doi:10.1007/s00228-013-1530-823748748
   PubMed Web of Science ®Google Scholar
• Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A4 activity and elvitegravir oral exposure. Clin Pharmacol Ther. 2009;85(1):64–70. doi:10.1038/clpt.2008.16818815591
   PubMed Web of Science ®Google Scholar
• Malingre MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol. 2001;19(4):1160–1166. doi:10.1200/JCO.2001.19.4.116011181682
   PubMed Web of Science ®Google Scholar
• Hendrikx JJMA, Lagas JS, Wagenaar E, et al. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. Br J Cancer. 2014;110(11):2669–2676. doi:10.1038/bjc.2014.22224781280
   PubMed Web of Science ®Google Scholar
• Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333(23):1528–1533. doi:10.1056/NEJM1995120733323037477167
   PubMed Web of Science ®Google Scholar
• Nieuweboer AJ, De Morrée ES, De Graan AJ, Sparreboom A, De Wit R, Mathijssen RH. Inter-patient variability in docetaxel pharmacokinetics: a review. Cancer Treat Rev. 2015;41(7):605–613. doi:10.1016/j.ctrv.2015.04.01225980322
   PubMed Web of Science ®Google Scholar
• Vermunt M, Robbrecht D, Devriese L, et al. ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): a multicenter phase I study. ASCO 2020 Genitourinary Cancer Symposium. J Clin Oncol. 2020;38(suppl6):79. doi:10.1200/JCO.2020.38.6_suppl.79
   Google Scholar
• Frederiks CN, Lam SW, Guchelaar HJ, Boven E. Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: a systematic review. Cancer Treat Rev. 2015;41(10):935–950. doi:10.1016/j.ctrv.2015.10.01026585358
   PubMed Web of Science ®Google Scholar
• Bosch TM, Huitema ADR, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res. 2006;12(19):5786–5793. doi:10.1158/1078-0432.CCR-05-264917020985
   PubMed Web of Science ®Google Scholar
• Kenmotsu H, Imamura C, Ono A, et al. The effects of advanced age and serum alpha1-acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients. Br J Clin Pharmacol. 2017;83(11):2416–2425. doi:10.1111/bcp.1335428640540
   PubMed Web of Science ®Google Scholar
• Jabir RS, Ho GF, Annuar MABA, Stanslas J. Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients. Biomarkers. 2018;23(2):142–146. doi:10.1080/1354750X.2017.133415228554261
   PubMed Web of Science ®Google Scholar
• Bruno R, Olivares R, Berille J, et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res. 2003;9(3):1077–1082.12631610
   PubMed Web of Science ®Google Scholar
• Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacother. 2003;74(4):364–371.
   Google Scholar